로딩 중...
52주 최고가 대비 89.8% 위치
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $2.97B | $2.96B | $2.96B | $3.17B |
| 영업이익 | - | $883.2M | $817.7M | $837.9M | $802.6M |
| 당기순이익 | - | $707.8M | $642.2M | $637.8M | $642.6M |
| 잉여현금흐름 (FCF) | - | $428.2M | $442.2M | $619.6M | $539.8M |
| 수익성 비율 | |||||
| 영업이익률 | - | 29.7% | 27.7% | 28.3% | 25.4% |
| 순이익률 | - | 23.8% | 21.7% | 21.6% | 20.3% |
| ROE (자기자본이익률) | - | 140.3% | 55.8% | 34.9% | 25.1% |
| ROA (자산이익률) | - | 21.6% | 13.9% | 14.0% | 12.7% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | -0.5% | 0.1% | 7.0% |
| EPS 성장률 (YoY) | - | - | -7.6% | -1.2% | 0.5% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 28.0x | 29.3x | 38.8x | 34.5x |
| PBR (주가순자산배수) | - | 63.9x | 27.1x | 22.3x | 14.2x |
| PSR (주가매출배수) | - | 10.9x | 10.6x | 13.8x | 11.5x |
| FCF Yield | - | 1.3% | 1.4% | 1.5% | 1.5% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 3.30 | 2.12 | 0.93 | 0.58 |
| 유동비율 | - | 2.24 | 2.22 | 2.11 | 1.73 |
MOLINA HEALTHCARE INC
$179.86
$9.4B